Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Amortization of Deferred Charges (2019 - 2025)

Historic Amortization of Deferred Charges for Karyopharm Therapeutics (KPTI) over the last 9 years, with Q4 2025 value amounting to $2.4 million.

  • Karyopharm Therapeutics' Amortization of Deferred Charges rose 373.36% to $2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.5 million, marking a year-over-year increase of 6558.33%. This contributed to the annual value of $10.5 million for FY2025, which is 6558.33% up from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Amortization of Deferred Charges is $2.4 million, which was up 373.36% from $2.8 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Amortization of Deferred Charges peaked at $2.8 million during Q3 2025, and registered a low of $191000.0 during Q1 2021.
  • Over the past 5 years, Karyopharm Therapeutics' median Amortization of Deferred Charges value was $206500.0 (recorded in 2023), while the average stood at $966050.0.
  • Per our database at Business Quant, Karyopharm Therapeutics' Amortization of Deferred Charges crashed by 9063.97% in 2021 and then soared by 113701.92% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Amortization of Deferred Charges stood at $199000.0 in 2021, then grew by 5.53% to $210000.0 in 2022, then rose by 3.33% to $217000.0 in 2023, then soared by 986.18% to $2.4 million in 2024, then rose by 3.73% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q4 2025, $2.8 million for Q3 2025, and $2.7 million during Q2 2025.